Chemokine (C-C Motif) Ligand 2 (CCL2) in Sera of Patients with Type 1 Diabetes and Diabetic Complications

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2011 May 3

PMID 21532752

Citations 21

Authors

Ruili Guan

Sharad Purohit

Hongjie Wang

Bruce Bode

John Chip Reed

R Dennis Steed

Stephen W Anderson

Leigh Steed

Diane Hopkins

Chun Xia

Jin-Xiong She

Affiliations

Soon will be listed here.

Abstract

Background: Chemokine (C-C motif) ligand 2 (CCL2), commonly known as monocyte chemoattractant protein-1 (MCP-1), has been implicated in the pathogenesis of many diseases characterized by monocytic infiltration. However, limited data have been reported on MCP-1 in type 1 diabetes (T1D) and the findings are inconclusive and inconsistent.

Methods: In this study, MCP-1 was measured in the sera from 2,472 T1D patients and 2,654 healthy controls using a Luminex assay. The rs1024611 SNP in the promoter region of MCP-1 was genotyped for a subset of subjects (1764 T1D patients and 1323 controls) using the TaqMan-assay.

Results: Subject age, sex or genotypes of MCP-1 rs1024611SNP did not have a major impact on serum MCP-1 levels in either healthy controls or patients. While hemoglobin A1c levels did not have a major influence on serum MCP-1 levels, the mean serum MCP-1 levels are significantly higher in patients with multiple complications (mean = 242 ng/ml) compared to patients without any complications (mean = 201 ng/ml) (p = 3.5×10(-6)). Furthermore, mean serum MCP-1 is higher in controls (mean = 261 ng/ml) than T1D patients (mean = 208 ng/ml) (p<10(-23)). More importantly, the frequency of subjects with extremely high levels (>99(th) percentile of patients or 955 ng/ml) of serum MCP-1 is significantly lower in the T1D group compared to the control group (odds ratio = 0.11, p<10(-33)).

Conclusion: MCP-1 may have a dual role in T1D and its complications. While very high levels of serum MCP-1 may be protective against the development of T1D, complications are associated with higher serum MCP-1 levels within the T1D group.

Citing Articles

Regulatory effects of statins on CCL2/CCR2 axis in cardiovascular diseases: new insight into pleiotropic effects of statins.

Gholamalizadeh H, Ensan B, Karav S, Jamialahmadi T, Sahebkar A J Inflamm (Lond). 2024; 21(1):51.

PMID: 39696507 PMC: 11658147. DOI: 10.1186/s12950-024-00420-y.

Distinct association patterns of chemokine profile and cardiometabolic status in children and adolescents with type 1 diabetes and obesity.

Spehar Uroic A, Filipovic M, Sucur A, Kelava T, Kovacic N, Grcevic D Front Endocrinol (Lausanne). 2024; 15:1335371.

PMID: 39109081 PMC: 11300205. DOI: 10.3389/fendo.2024.1335371.

Recent Advances in the Emerging Therapeutic Strategies for Diabetic Kidney Diseases.

Huang W, Chen Y, Li Z, He F, Zhang C Int J Mol Sci. 2022; 23(18).

PMID: 36142794 PMC: 9506036. DOI: 10.3390/ijms231810882.

Chemokines in Type 1 Diabetes Mellitus.

Pan X, Kaminga A, Kinra S, Wen S, Liu H, Tan X Front Immunol. 2022; 12():690082.

PMID: 35242125 PMC: 8886728. DOI: 10.3389/fimmu.2021.690082.

New Evidence in the Pathogenesis of Celiac Disease and Type 1 Diabetes Mellitus: A Systematic Review.

Prieto J, Singh K, Nnadozie M, Abdal M, Shrestha N, Abe R Cureus. 2021; 13(7):e16721.

PMID: 34513356 PMC: 8405172. DOI: 10.7759/cureus.16721.

References

Antonelli A, Ferri C, Fallahi P, Ferrari S, Frascerra S, Pampana A . CXCL10 and CCL2 chemokine serum levels in patients with hepatitis C associated with autoimmune thyroiditis. J Interferon Cytokine Res. 2009; 29(6):345-51. DOI: 10.1089/jir.2008.0090. View

Scarpini E, Galimberti D, Baron P, Clerici R, Ronzoni M, Conti G . IP-10 and MCP-1 levels in CSF and serum from multiple sclerosis patients with different clinical subtypes of the disease. J Neurol Sci. 2002; 195(1):41-6. DOI: 10.1016/s0022-510x(01)00680-3. View

Liu S, Wang H, Jin Y, Podolsky R, Reddy M, Pedersen J . IFIH1 polymorphisms are significantly associated with type 1 diabetes and IFIH1 gene expression in peripheral blood mononuclear cells. Hum Mol Genet. 2008; 18(2):358-65. PMC: 2638779. DOI: 10.1093/hmg/ddn342. View

Kokkotou E, Marafelia P, Mantzos E, Tritos N . Serum monocyte chemoattractant protein-1 is increased in chronic autoimmune thyroiditis. Metabolism. 2002; 51(11):1489-93. DOI: 10.1053/meta.2002.34717. View

Rollins B, Pober J . Interleukin-4 induces the synthesis and secretion of MCP-1/JE by human endothelial cells. Am J Pathol. 1991; 138(6):1315-9. PMC: 1886397. View

Antonelli A, Fallahi P, Delle Sedie A, Ferrari S, Maccheroni M, Bombardieri S . High values of alpha (CXCL10) and beta (CCL2) circulating chemokines in patients with psoriatic arthritis, in presence or absence of autoimmune thyroiditis. Autoimmunity. 2008; 41(7):537-42. DOI: 10.1080/08916930802170401. View

Tesch G . MCP-1/CCL2: a new diagnostic marker and therapeutic target for progressive renal injury in diabetic nephropathy. Am J Physiol Renal Physiol. 2008; 294(4):F697-701. DOI: 10.1152/ajprenal.00016.2008. View

Antonelli A, Ferri C, Fallahi P, Ferrari S, Frascerra S, Franzoni F . CXCL10 and CCL2 serum levels in patients with mixed cryoglobulinaemia and hepatitis C. Dig Liver Dis. 2008; 41(1):42-8. DOI: 10.1016/j.dld.2008.04.009. View

Kim C, Park H, Kawada T, Kim J, Lim D, Hubbard N . Circulating levels of MCP-1 and IL-8 are elevated in human obese subjects and associated with obesity-related parameters. Int J Obes (Lond). 2006; 30(9):1347-55. DOI: 10.1038/sj.ijo.0803259. View

10.

Rovin B, Lu L, Saxena R . A novel polymorphism in the MCP-1 gene regulatory region that influences MCP-1 expression. Biochem Biophys Res Commun. 1999; 259(2):344-8. DOI: 10.1006/bbrc.1999.0796. View

11.

Radstake T, Vonk M, Dekkers M, Schijvenaars M, Treppichio W, Lafyatis R . The -2518A>G promoter polymorphism in the CCL2 gene is not associated with systemic sclerosis susceptibility or phenotype: results from a multicenter study of European Caucasian patients. Hum Immunol. 2008; 70(2):130-3. DOI: 10.1016/j.humimm.2008.10.012. View

12.

Berman M, Sandborg C, Wang Z, Imfeld K, Zaldivar Jr F, Dadufalza V . Decreased IL-4 production in new onset type I insulin-dependent diabetes mellitus. J Immunol. 1996; 157(10):4690-6. View

13.

Stankovic A, Slavic V, Stamenkovic B, Kamenov B, Bojanovic M, Mitrovic D . Serum and synovial fluid concentrations of CCL2 (MCP-1) chemokine in patients suffering rheumatoid arthritis and osteoarthritis reflect disease activity. Bratisl Lek Listy. 2009; 110(10):641-6. View

14.

Del Guerra S, DAleo V, Gualtierotti G, Filipponi F, Boggi U, De Simone P . A common polymorphism in the monocyte chemoattractant protein-1 (MCP-1) gene regulatory region influences MCP-1 expression and function of isolated human pancreatic islets. Transplant Proc. 2010; 42(6):2247-9. DOI: 10.1016/j.transproceed.2010.05.039. View

15.

Sia C . Imbalance in Th cell polarization and its relevance in type 1 diabetes mellitus. Rev Diabet Stud. 2007; 2(4):182-6. PMC: 1783566. DOI: 10.1900/RDS.2005.2.182. View

16.

Tarabra E, Giunti S, Barutta F, Salvidio G, Burt D, Deferrari G . Effect of the monocyte chemoattractant protein-1/CC chemokine receptor 2 system on nephrin expression in streptozotocin-treated mice and human cultured podocytes. Diabetes. 2009; 58(9):2109-18. PMC: 2731530. DOI: 10.2337/db08-0895. View

17.

Kanamori H, Matsubara T, Mima A, Sumi E, Nagai K, Takahashi T . Inhibition of MCP-1/CCR2 pathway ameliorates the development of diabetic nephropathy. Biochem Biophys Res Commun. 2007; 360(4):772-7. DOI: 10.1016/j.bbrc.2007.06.148. View

18.

Harsimran K, Singh A, Guruvinder S, Sharda S, Vasudha S . Plasma monocyte chemoattractant protein-1 as risk marker in type 2 diabetes mellitus and coronary artery disease in North Indians. Diab Vasc Dis Res. 2010; 6(4):288-90. DOI: 10.1177/1479164109346364. View

19.

Antonelli A, Fallahi P, Delle Sedie A, Ferrari S, Maccheroni M, Bombardieri S . High values of Th1 (CXCL10) and Th2 (CCL2) chemokines in patients with psoriatic arthtritis. Clin Exp Rheumatol. 2009; 27(1):22-7. View

20.

Kiyici S, Erturk E, Budak F, Ersoy C, Tuncel E, Duran C . Serum monocyte chemoattractant protein-1 and monocyte adhesion molecules in type 1 diabetic patients with nephropathy. Arch Med Res. 2006; 37(8):998-1003. DOI: 10.1016/j.arcmed.2006.06.002. View